11:26 AM EDT, 06/11/2024 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) said Tuesday the US Patent and Trademark Office has granted another patent for the company's obicetrapib, which is being developed to overcome the limitations of current low-density lipoprotein cholesterol treatments.

The newly issued patent protects the amorphous obicetrapib hemicalcium, the solid form that will be used in the company's product candidate, the company said.

The latest patent extends the intellectual property protection for the product candidate until July 2043. Obicetrapib and its uses are now covered by a total of nine patents issued by the US agency, the company said.

Price: 19.63, Change: -0.05, Percent Change: -0.25